Received Apr 8, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | A3X2K | — |
Pediatric dose to a 50 YO patient; Pediatric dose to a 50 YO patient; This non-serious case was reported by a other health professional via call center representative and described the occurrence of adult use of a child product in a 50-year-old female patient who received HAV (Havrix 720) (batch number A3X2K) for prophylaxis. On 23-MAR-2026, the patient received Havrix 720. On 23-MAR-2026, an unknown time after receiving Havrix 720, the patient experienced adult use of a child product (Verbatim: Pediatric dose to a 50 YO patient) and underdose (Verbatim: Pediatric dose to a 50 YO patient). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK receipt date 02-APR-2026 The reporter consented to follow up. The vaccine administration facility was the same as primary reporter.